In an artificial endosphincter (1) for the urethra, comprising a retaining part (2) and a valve (10) which can be manually actuated by pressure from the outside, the retaining part (2) is formed as self-expanding stent. This permits gentle, simple and safe positioning as well as reliable and simple handling of the artificial endosphincter (1).
|
1. An artificial endosphincter for a urethra, the endosphincter comprising:
a retaining part, structured as a temperature-independent, self-expanding stent; and
a valve which can be manually actuated by external pressure, wherein said valve is a self-closing, crossed slotted valve.
2. The endosphincter of
3. The endosphincter of
5. The endosphincter of
8. The endosphincter of
9. The endosphincter of
10. The endosphincter of
12. The endosphincter of
13. The endosphincter of
14. The endosphincter of
15. The endosphincter of
17. The endosphincter of
18. The endosphincter of
19. The endosphincter of
20. The endosphincter of
|
This application claims Paris Convention priority of DE 102 56 027.7 filed Nov. 30, 2002, the complete disclosure of which is hereby incorporated by reference.
The invention concerns an artificial endosphincter for the urethra comprising a retaining part and a valve which can be manually actuated by pressure from the outside.
An artificial endosphincter of this type is disclosed e.g. in EP 96 018 05.
Artificial endosphincters are used for incontinency therapy for men after a prostrate resection and for “old incontinent men”. The urethra lies between the two cavernous bodies on the lower side of the penis. The urethra is pressed from below by thumb and index finger against the upward lying, parallel cavernous bodies. The pressure on the urethra also exerts pressure on the manually actuatable valve which should thereby open. Since the urethra is surrounded by the cavernous bodies through approximately 270°, the artificial endosphincter must be positioned such that the valve can be opened by a pressure manually built up from the outside through a relatively narrow angular region of the urethra of approximately 90°.
U.S. Pat. No. 6,022,312 discloses an artificial endosphincter whose retaining part has two different diameters, wherein a valve body is mounted to that retaining part section having the smaller diameter. The artificial endosphincter has a holding region between the retaining part having a smaller diameter and the retaining part having a larger diameter. The conventional retaining part is introduced, in an insertion configuration, into a hollow organ and is then expanded by the body temperature. The valve body also comprises two sealing lips which enclose a slitted opening. The sealing lips must be disposed parallel to the actuating direction in the urethra and must therefore be properly oriented when the artificial endosphincter is positioned. If this is not possible, the sealing lips may come to rest transversely or perpendicularly to the actuating direction. In this case, finger pressure can no longer open the valve, rather closes it more tightly.
It is therefore the object of the present invention to further develop an artificial endosphincter of the above-mentioned type such that it can be expanded independently of temperature and/or has a valve which can be opened independently of position.
This object is achieved in accordance with the invention in that the retaining part is formed as a self-expanding stent.
A self-expanding stent avoids the need for expansion using a balloon or based on increased temperatures. Introduction of the stent is greatly facilitated. For introduction, the stent can be compressed e.g. through extension thereof. After insertion it automatically expands substantially to the shape it had prior to compression. The self-expanding stent is flexible and can follow the curvature of the urethra.
In one preferred embodiment, the sent is a tubular interlacing which is produced from at least one filament. Production of a self-expanding stent with such a tubular interlacing is particularly straightforward.
The inventive artificial endosphincter can preferably be shortened e.g. by simply cutting the stent. Towards this end, the stent has sections without tubular interlacing at which the stent can be easily cut off. This permits individual adjustment and adaptation of the artificial endosphincter to each patient and a relatively short retaining part can be used for incontinence therapy. In case of acute urinary retention or blockage, the uncut retaining part can be used to circumvent the functioning sphincter.
In a preferred embodiment of the invention, the at least one filament has a round cross-section. This is advantageous in that the tissue of the urethra can adapt well to the stent and the tissue is not injured when the stent is inserted and removed. Depending on the application of the stent, it may be advantageous to select a filament with different cross-section, e.g. rectangular, triangular or elliptical.
In a particularly preferred embodiment of the invention, the at least one filament is produced from plastic material or metal. A stent produced from these materials has a type of “shape memory” and therefore displays the so-called “memory effect”. Following compression, the tubular interlacing always returns to its expanded, initial state. The tubular interlacing can be compressed to introduce the stent with a small lumen. After introduction into the urethra, the stent automatically expands to produce a large stent lumen for unobstructed urine flow to the valve.
The artificial endosphincter advantageously has X-ray impermeable markings, in particular at its ends. In this way, the position of the artificial endosphincter can be monitored using radiographs. The X-ray impermeable markings may be provided only on the stent.
A cylindrical stent advantageously facilitates removal of the endosphincter in a particularly easy manner, since the stent has no bulge which could impair displacement in the urethra. A cylindrical stent can be compressed to a particularly small size and therefore be inserted without causing significant irritation.
A stent with at least two cylindrical sections of different radii advantageously allows its restoring force to be adjusted to different areas in e.g. the region of the prostrate or of the annular muscle connecting to the bladder. A sufficiently large lumen of the endosphincter can therefore be guaranteed. The stent may have other advantageous shapes, e.g. bulged shapes, and lumen enlargements in sections, in dependence on the application.
In a particularly preferred embodiment, the tubular interlacing has both an inside and outside coating creating a flat inner surface and manifesting the interlacing structure on the outer surface. The flat inner surface permits good flow of urine in the stent and prevents deposits (incrustations). The coating on the outer surface of the stent is preferably thinner than the diameter of the filament such that the structure of the tubular interlacing is maintained and the stent is thereby held stationary in the urethra. In particular, the tubular interlacing surrounds a tube on the surface of which a coating is applied to hold the tubular interlacing on the tube. The coating which holds the tubular interlacing on the tube is preferably made from the same material as the tube. This provides particularly good e.g. material-bonding connection of the two coatings.
In a preferred further development, the tube terminates in a valve receptacle. With this measure, the valve receptacle is held at the retaining part. It is also possible to form the tube and valve receptacle from the same material as one single piece.
When the transition region between valve receptacle and tube is conical, the valve receptacle may have a smaller diameter than the tube. This transition region permits compression of the tube and thereby also of the stent to approximately the diameter of the valve receptacle. Due to this measure, the artificial endosphincter is not damaged during positioning.
In a further development, the transition region is coated by the tubular interlacing. This measure facilitates removal of the artificial endosphincter from the urethra.
When the filaments of the tubular interlacing taper along the transition region towards the valve receptacle, the elasticity and flexibility of the transition region is also maintained at the valve-side end. Formation of a rigid material ring of compressed filaments with equal thickness is thereby avoided.
In a particularly preferred fashion, the tube and valve receptacle are formed in one piece, in particular, from silicone. The one-piece design permits inexpensive production of the endosphincter and simplifies assembly of the endosphincter. Silicone is a highly-flexible material which can be deformed during positioning and automatically assumes its original shape after positioning is completed. In particular, it is important that the valve receptacle returns to its original shape after actuation of the valve and automatic closure thereof following intentional opening.
In a particularly preferred embodiment, the valve is an automatically closing, crossed slotted valve. The use of a crossed slotted valve is highly advantageous in that the valve can be actuated at almost any position in the urethra and the orientation of the artificial endosphincter following positioning in the urethra is unimportant. Inadvertent closing of the valve while exerting pressure on the urethra is not possible and malfunction is nearly impossible.
In a particularly preferred embodiment, the crossed slotted valve has a hollow cylindrical mounting section and a closing section facing the retaining part. The valve is held in the valve receptacle by the hollow-cylindrical mounting section. The mounting section thereby abuts with its outer surface on the inner surface of the valve receptacle. The valve is positively held with the mounting section in the valve receptacle. Since the closing section of the crossed slotted valve faces the retaining part, closing of the crossed slotted valve is facilitated in response to liquid pressure in an axial direction of the artificial endosphincter. The higher the pressure which is exerted on the closing section, the better the valve closes.
In a preferred further development, the crossed slotted valve has pressure receiving surfaces. These pressure receiving surfaces can accept static pressure from four sides, to ensure good closure of the sealing lips.
The crossed slotted valve is advantageously produced from silicone. When the crossed slotted valve and the valve receptacle are produced from the same material, they are uniformly deformed when pressure is exerted on the urethra. Due to the elastic properties of silicone, the valve and the valve receptacle return to their original positions when no pressure is exerted. The crossed slotted valve thereby closes automatically when no radial pressure is exerted on the urethra.
Further features and advantages of the invention can be extracted from the following description of an embodiment of the invention, from the figures of the drawing which show details which are essential to the invention, and from the claims. The individual features can be realized individually or collectively in arbitrary combination in variations of the invention.
The schematic drawing shows one embodiment of the inventive artificial endosphincter which is explained in the following description.
The figures are highly schematic to illustrate the essential inventive features. The dimensions in the drawings are only exemplary and are not to be taken to scale.
An artificial endosphincter 1 for the urethra comprises a retaining part 2 and a valve 10 which can be manually actuated from outside through pressure, the retaining part 2 being formed as a self-expanding stent. This permits gentle, simple and safe positioning as well as reliable and simple handling of the artificial endosphincter 1.
Chaussy, Christian, Schmitt, Klaus, Thüroff, Stefan
Patent | Priority | Assignee | Title |
10952836, | Jul 17 2009 | KIRK PROMOTION LTD | Vaginal operation method for the treatment of urinary incontinence in women |
11560953, | Jun 30 2020 | Illinois Tool Works Inc. | Anti-free-flow valve |
8678997, | Feb 14 2000 | Obtech Medical AG | Male impotence prosthesis apparatus with wireless energy supply |
8734318, | Feb 11 2000 | Obtech Medical AG | Mechanical anal incontinence |
8764627, | Feb 14 2000 | Obtech Medical AG | Penile prosthesis |
9949812, | Jul 17 2009 | KIRK PROMOTION LTD | Vaginal operation method for the treatment of anal incontinence in women |
Patent | Priority | Assignee | Title |
4655771, | Apr 30 1982 | AMS MEDINVENT S A | Prosthesis comprising an expansible or contractile tubular body |
4968294, | Feb 09 1989 | OPTICON MEDICAL INC | Urinary control valve and method of using same |
5078720, | May 02 1990 | AMS Research Corporation | Stent placement instrument and method |
5800339, | Feb 09 1989 | OPTICON MEDICAL INC | Urinary control valve |
5954766, | Sep 16 1997 | Pulmonx Corporation | Body fluid flow control device |
5971967, | Aug 19 1997 | ABBEYMOOR MEDICAL, INC | Urethral device with anchoring system |
6022312, | May 05 1995 | CHAUSSY, CHRISTIAN | Endosphincter, set for releasable closure of the urethra and method for introduction of an endosphincter into the urethra |
6162244, | Mar 29 1996 | Boston Scientific Scimed, Inc | Layered stent |
6488702, | Jan 24 1997 | CELONOVA STENT, INC | Bistable spring construction for a stent and other medical apparatus |
DE19509464, | |||
DE29507519, | |||
WO9832412, | |||
WO9913801, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Nov 13 2003 | CHAUSSY, CHRISTIAN | WILLY RUESCH GMBH | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 014957 | /0905 | |
Nov 13 2003 | THUEROFF, STEFAN | WILLY RUESCH GMBH | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 014957 | /0905 | |
Nov 14 2003 | SCHMITT, KLAUS | WILLY RUESCH GMBH | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 014957 | /0905 | |
Nov 21 2003 | Willy Rüsch GmbH | (assignment on the face of the patent) | / | |||
Oct 18 2005 | WILLY RUESCH GMBH | CHRISTIAN CHAUSSY | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 016985 | /0059 | |
Oct 18 2005 | WILLY RUESCH GMBH | STEFAN THUEROFF | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 016985 | /0059 | |
Oct 18 2005 | WILLY RUESCH GMBH | KLAUS SCHMITT | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 016985 | /0059 | |
Jan 17 2012 | THUROFF, STEFAN | CHAUSSY, CHRISTIAN | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 027672 | /0302 |
Date | Maintenance Fee Events |
Sep 16 2009 | ASPN: Payor Number Assigned. |
Dec 16 2009 | M2551: Payment of Maintenance Fee, 4th Yr, Small Entity. |
Dec 16 2009 | M2554: Surcharge for late Payment, Small Entity. |
Dec 29 2009 | LTOS: Pat Holder Claims Small Entity Status. |
Dec 29 2009 | R1551: Refund - Payment of Maintenance Fee, 4th Year, Large Entity. |
Sep 02 2013 | M2552: Payment of Maintenance Fee, 8th Yr, Small Entity. |
Oct 16 2017 | REM: Maintenance Fee Reminder Mailed. |
Apr 02 2018 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
Date | Maintenance Schedule |
Mar 07 2009 | 4 years fee payment window open |
Sep 07 2009 | 6 months grace period start (w surcharge) |
Mar 07 2010 | patent expiry (for year 4) |
Mar 07 2012 | 2 years to revive unintentionally abandoned end. (for year 4) |
Mar 07 2013 | 8 years fee payment window open |
Sep 07 2013 | 6 months grace period start (w surcharge) |
Mar 07 2014 | patent expiry (for year 8) |
Mar 07 2016 | 2 years to revive unintentionally abandoned end. (for year 8) |
Mar 07 2017 | 12 years fee payment window open |
Sep 07 2017 | 6 months grace period start (w surcharge) |
Mar 07 2018 | patent expiry (for year 12) |
Mar 07 2020 | 2 years to revive unintentionally abandoned end. (for year 12) |